Jade Biosciences (JBIO)
Jade Biosciences on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.
11.2M
Short interest
settlement 2026-10-15
10.9
Days to cover
-0.5 days vs prior
54.8%
Short share of volume
2026-11-02
3,391
Fails to deliver
settlement 2026-10-14
Fri 13 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 36 settlements in the table, 36 in the chart. JSONAs of 15 October 2026, short interest in JBIO is 11,210,801 shares, up 227,896 shares over the last month. Over the last 36 readings it ranged from 147,956 shares (30 April 2025) to 12,119,108 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 1.0M shares a day that is 10.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/jbio" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 11,210,801 | -7.5% | 1,031,218 | 10.87 |
| 2026-09-30 | 12,119,108 | +10.3% | 1,069,456 | 11.33 |
| 2026-09-15 | 10,982,905 | +9.9% | 933,970 | 11.76 |
| 2026-08-31 | 9,994,410 | +3.6% | 606,567 | 16.48 |
| 2026-08-14 | 9,650,429 | +11.0% | 951,158 | 10.15 |
| 2026-07-31 | 8,690,697 | +15.4% | 755,922 | 11.50 |
| 2026-07-15 | 7,528,320 | -7.6% | 1,052,173 | 7.16 |
| 2026-06-30 | 8,148,753 | +64.7% | 1,679,029 | 4.85 |
| 2026-06-15 | 4,947,659 | +56.4% | 1,595,743 | 3.10 |
| 2026-05-29 | 3,163,082 | -6.9% | 582,751 | 5.43 |
| 2026-05-15 | 3,398,202 | +9.7% | 443,565 | 7.66 |
| 2026-04-30 | 3,097,060 | +1.2% | 781,225 | 3.96 |
| 2026-04-15 | 3,061,277 | +144.6% | 809,621 | 3.78 |
| 2026-03-31 | 1,251,725 | -18.4% | 553,410 | 2.26 |
| 2026-03-13 | 1,534,939 | -1.7% | 348,505 | 4.40 |
| 2026-02-27 | 1,561,572 | +0.2% | 213,537 | 7.31 |
| 2026-02-13 | 1,558,822 | +7.7% | 226,599 | 6.88 |
| 2026-01-30 | 1,446,919 | +7.5% | 256,163 | 5.65 |
| 2026-01-15 | 1,345,619 | -13.0% | 314,286 | 4.28 |
| 2025-12-31 | 1,546,739 | +47.9% | 465,345 | 3.32 |
| 2025-12-15 | 1,046,137 | -10.2% | 319,990 | 3.27 |
| 2025-11-28 | 1,165,100 | +8.9% | 225,926 | 5.16 |
| 2025-11-14 | 1,069,346 | +3.9% | 221,324 | 4.83 |
| 2025-10-31 | 1,029,313 | -39.6% | 189,526 | 5.43 |
| 2025-10-15 | 1,705,247 | -2.9% | 211,577 | 8.06 |
| 2025-09-30 | 1,756,044 | +0.7% | 71,413 | 24.59 |
| 2025-09-15 | 1,743,879 | -3.5% | 56,639 | 30.79 |
| 2025-08-29 | 1,807,489 | -4.9% | 107,366 | 16.83 |
| 2025-08-15 | 1,900,704 | +4.5% | 103,490 | 18.37 |
| 2025-07-31 | 1,819,583 | -2.5% | 136,019 | 13.38 |
| 2025-07-15 | 1,865,916 | -7.9% | 212,370 | 8.79 |
| 2025-06-30 | 2,026,234 | +433.9% | 1,007,665 | 2.01 |
| 2025-06-13 | 379,537 | +59.2% | 345,349 | 1.10 |
| 2025-05-30 | 238,419 | +46.3% | 328,546 | 1.00 |
| 2025-05-15 | 162,947 | +10.1% | 231,587 | 1.00 |
| 2025-04-30 | 147,956 | -96.8% | 73,592 | 2.01 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of JBIO volume is 54.8%, down 32.4 points over the last five sessions. Over the last 30 readings it ranged from 20.0% (23 September 2026) to 87.2% (26 October 2026). The latest reading is 2.3 points below the 30-session average of 57.0%, on 267K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 146K | 267K | 54.8% | 0 |
| 2026-10-30 | 121K | 234K | 51.8% | 0 |
| 2026-10-29 | 127K | 371K | 34.4% | 0 |
| 2026-10-28 | 127K | 358K | 35.4% | 0 |
| 2026-10-27 | 192K | 237K | 81.0% | 0 |
| 2026-10-26 | 152K | 174K | 87.2% | 0 |
| 2026-10-23 | 160K | 244K | 65.7% | 0 |
| 2026-10-22 | 132K | 203K | 65.2% | 0 |
| 2026-10-21 | 313K | 388K | 80.7% | 0 |
| 2026-10-20 | 249K | 338K | 73.5% | 0 |
| 2026-10-19 | 253K | 319K | 79.1% | 0 |
| 2026-10-16 | 253K | 342K | 74.1% | 0 |
| 2026-10-15 | 235K | 356K | 66.1% | 0 |
| 2026-10-14 | 275K | 514K | 53.5% | 0 |
| 2026-10-13 | 409K | 615K | 66.6% | 0 |
| 2026-10-12 | 242K | 867K | 27.9% | 0 |
| 2026-10-09 | 187K | 317K | 58.9% | 0 |
| 2026-10-08 | 270K | 645K | 41.9% | 0 |
| 2026-10-07 | 167K | 317K | 52.5% | 0 |
| 2026-10-06 | 106K | 219K | 48.6% | 0 |
| 2026-10-05 | 113K | 253K | 44.7% | 0 |
| 2026-10-02 | 164K | 565K | 29.0% | 0 |
| 2026-10-01 | 239K | 499K | 47.9% | 324 |
| 2026-09-30 | 210K | 311K | 67.7% | 0 |
| 2026-09-29 | 149K | 225K | 66.1% | 0 |
| 2026-09-28 | 92K | 172K | 53.6% | 0 |
| 2026-09-25 | 136K | 202K | 67.2% | 0 |
| 2026-09-24 | 207K | 472K | 43.8% | 5,938 |
| 2026-09-23 | 147K | 735K | 20.0% | 2,736 |
| 2026-09-22 | 234K | 323K | 72.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in JBIO is 3,391 shares, up 1,677 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (25 June 2026) to 49,666 shares (3 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 3,391 | $13.42 | $46K |
| 2026-10-06 | 1,714 | $14.07 | $24K |
| 2026-10-05 | 2,734 | $14.12 | $39K |
| 2026-10-02 | 747 | $13.77 | $10K |
| 2026-10-01 | 1,662 | $14.05 | $23K |
| 2026-09-30 | 838 | $14.18 | $12K |
| 2026-09-28 | 3,244 | $14.42 | $47K |
| 2026-09-25 | 3,473 | $14.73 | $51K |
| 2026-09-23 | 1,364 | $16.76 | $23K |
| 2026-09-18 | 3,535 | $17.14 | $61K |
| 2026-08-03 | 49,666 | $19.75 | $981K |
| 2026-07-16 | 18 | $21.86 | $393 |
| 2026-07-13 | 8 | $20.95 | $168 |
| 2026-07-08 | 710 | $22.45 | $16K |
| 2026-07-07 | 9 | $21.30 | $192 |
| 2026-07-06 | 30 | $21.51 | $645 |
| 2026-07-02 | 1,000 | $21.81 | $22K |
| 2026-07-01 | 2,303 | $22.22 | $51K |
| 2026-06-30 | 2,598 | $22.11 | $57K |
| 2026-06-29 | 207 | $22.00 | $5K |
| 2026-06-26 | 208 | $21.81 | $5K |
| 2026-06-25 | 1 | $21.90 | $22 |
| 2026-06-22 | 6 | $16.82 | $101 |
| 2026-06-17 | 48,797 | $15.53 | $758K |
| 2026-06-15 | 108 | $15.34 | $2K |
| 2026-06-08 | 2,700 | $16.94 | $46K |
| 2026-05-21 | 22,622 | $23.34 | $528K |
| 2026-05-13 | 723 | $25.23 | $18K |
| 2026-05-12 | 90 | $24.86 | $2K |
| 2026-05-01 | 234 | $24.40 | $6K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for JBIO in the last 90 days. The most recent filings are listed below. Latest filing: King Andrew James (See Remarks) on 2026-02-12.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-02-12 | King Andrew James | See Remarks | Grant | 41K | $0.00 | $0 | 386K |
| 2026-02-12 | Frohlich Tom | Chief Executive Officer | Grant | 79K | $0.00 | $0 | 86K |
| 2026-02-12 | Dahms Bradford D. | Chief Financial Officer | Grant | 38K | $0.00 | $0 | 38K |
| 2026-02-12 | Balta Elizabeth | See Remarks | Grant | 28K | $0.00 | $0 | 28K |
| 2025-10-06 | Fairmount Healthcare Fund II L.P. | Director,TenPercentOwner | Grant | 1.3M | $9.14 | $12.2M | 1.9M |
| 2025-10-06 | Fairmount Funds Management LLC | Director, 10% owner | Grant | 1.3M | $9.14 | $12.2M | 1.9M |
| 2025-05-16 | Frohlich Tom | Chief Executive Officer | Buy | 6K | $7.40 | $44K | 6K |
| 2025-04-28 | Kolchinsky Peter | TenPercentOwner | Other transaction | 1.1M | price not stated in the filing | not stated | 1.3M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON24 holders report 5% or more of JBIO in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is Tomas Kiselak at 20.0% of the class (14,063,511 shares), filed 2026-06-09 for an event on 2026-06-05.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-28 | 13G | Franklin Templeton, Inc.parent holding company, corporation | 3.8M | 6.0% | 2026-09-30 |
| 2026-10-28 | 13G | Rupert H. Johnson, Jr.parent holding company, individual | 0 | 0.0% | 2026-09-30 |
| 2026-10-28 | 13G | Charles B. Johnsonparent holding company, individual | 0 | 0.0% | 2026-09-30 |
| 2026-10-27 | 13G | BlackRock, Inc.parent holding company | 3.3M | 5.2% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 2 | Bong Y. Kohindividual | 5.1M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | VHCP Management EG, LLCother entity | 5.1M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Nimish Shahindividual | 5.1M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Venrock Healthcare Capital Partners III, L.P.partnership | 5.1M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | VHCP Co-Investment Holdings III, LLCother entity | 5.1M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Venrock Healthcare Capital Partners EG, L.P.partnership | 5.1M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | VHCP Management III, LLCother entity | 5.1M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Bellevue Asset Management AGcorporation | 3.1M | 5.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Bellevue Group AGparent holding company, corporation | 3.1M | 5.0% | 2026-06-30 |
| 2026-07-17 | 13G | Paradigm BioCapital Advisors LPpartnership | 3.1M | 5.1% | 2026-07-10 |
| 2026-07-17 | 13G | Paradigm BioCapital Advisors GP LLCother entity | 3.1M | 5.1% | 2026-07-10 |
| 2026-07-17 | 13G | Senai Asefaw, M.D.individual | 3.1M | 5.1% | 2026-07-10 |
| 2026-07-17 | 13G | Paradigm BioCapital International Fund Ltd.corporation | 2.7M | 4.5% | 2026-07-10 |
| 2026-07-08 | 13G/Ano. 2 | JANUS HENDERSON GROUP Ltd.parent holding company | 6.3M | 10.6% | 2026-06-30 |
| 2026-06-09 | 13D/Ano. 2 | Tomas Kiselakindividual | 14.1M | 20.0% | 2026-06-05 |
| 2026-06-09 | 13D/Ano. 2 | Peter Evan Harwinindividual | 14.1M | 20.0% | 2026-06-05 |
| 2026-06-09 | 13D/Ano. 2 | Fairmount Funds Management LLCinvestment adviser | 14.1M | 20.0% | 2026-06-05 |
| 2026-06-09 | 13D/Ano. 2 | Fairmount Healthcare Fund II L.P.partnership | 11.4M | 16.2% | 2026-06-05 |
| 2026-06-09 | 13D/Ano. 2 | Fairmount Healthcare Co-Invest IV L.P.partnership | 2.7M | 4.4% | 2026-06-05 |
| 2026-05-15 | 13G/Ano. 1 | JANUS HENDERSON GROUP PLCparent holding company | 3.1M | 6.3% | 2026-03-31 |
| 2026-03-05 | 13D/Ano. 3 | Sofinnova Management X, L.P. ("SM X LP")partnership | 107K | 0.3% | 2025-04-28 |
| 2026-03-05 | 13D/Ano. 3 | Sofinnova Management X-A, L.L.C. ("SM X LLC")other entity | 107K | 0.3% | 2025-04-28 |
| 2026-03-05 | 13D/Ano. 3 | Dr. James I. Healy ("Healy")individual | 107K | 0.3% | 2025-04-28 |
| 2026-03-05 | 13D/Ano. 3 | Dr. Maha Katabi ("Katabi")individual | 107K | 0.3% | 2025-04-28 |
| 2026-03-05 | 13D/Ano. 3 | Sofinnova Venture Partners X, L.P. ("SVP X")partnership | 107K | 0.3% | 2025-04-28 |
| 2026-02-13 | 13G/Ano. 2 | Deep Track Capital, LPinvestment adviser, other entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Deep Track Biotechnology Master Fund, Ltd.corporation | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | David Kroinparent holding company, individual | 0 | 0.0% | 2025-12-31 |
| 2026-01-30 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 2.1M | 4.2% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 2 | FHMLSP, L.L.C.other entity | 1.4M | 4.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | FHMLSP, L.P.partnership | 1.4M | 4.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Frazier Life Sciences Public Fund, L.P.partnership | 1.4M | 4.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Frazier Life Sciences XI, L.P.partnership | 19K | 0.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | FHMLS XI, L.P.partnership | 19K | 0.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | FHMLS XI, L.L.C.other entity | 19K | 0.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Patrick J. Heronindividual | 9K | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | James N. Topperindividual | 9K | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | FHMLS X, L.L.C.other entity | 9K | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | FHMLS X, L.P.partnership | 9K | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Frazier Life Sciences X, L.P.partnership | 9K | 0.0% | 2025-09-30 |
| 2025-10-16 | 13G | RA Capital Healthcare Fund, L.P.partnership | 3.2M | 7.0% | 2025-10-08 |
| 2025-10-16 | 13G | Rajeev Shahparent holding company, individual | 3.2M | 7.0% | 2025-10-08 |
| 2025-10-16 | 13G | Peter Kolchinskyparent holding company, individual | 3.2M | 7.0% | 2025-10-08 |
| 2025-10-16 | 13G | RA Capital Management, L.P.investment adviser, partnership | 3.2M | 7.0% | 2025-10-08 |
13F holders
Tracked managers holding JBIO at their latest 13F. JSON7 of the 30 tracked managers held JBIO at their latest 13F, $35.4M in total at quarter-end prices. Citadel Advisors is the largest at $20.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 929K | $20.7M | 0.00% | +792K |
| Millennium Management | 2026-06-30 | 315K | $7.0M | 0.00% | +154K |
| Point72 Asset Management | 2026-06-30 | 167K | $3.7M | 0.00% | -97K |
| Renaissance Technologies | 2026-06-30 | 74K | $1.6M | 0.00% | -61K |
| D. E. Shaw & Co. | 2026-06-30 | 51K | $1.1M | 0.00% | new |
| Two Sigma Investments | 2026-06-30 | 45K | $1.0M | 0.00% | +27K |
| AQR Capital Management | 2026-06-30 | 13K | $296K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Jade Biosciences in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Jade Biosciences (JBIO), SEC CIK 1798749, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-28.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-10.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-02-12.JSON and CSV
- Company record
- EDGAR filing index for CIK 1798749Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
- TDToronto-Dominion Bank
- TDGTransDigm Group
- TDYTeledyne Technologies
Datasets
Frequently Asked Questions
How much of JBIO is sold short?
What is JBIO's daily short volume?
Does JBIO have fails to deliver?
Are JBIO insiders buying or selling?
Who owns 5% or more of JBIO?
Which tracked 13F managers own JBIO?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.